Analysis-Hims & Hers stands to gain if the FDA loosens restrictions on peptides

By Amina Niasse July 23 - Hims & Hers Health is set to tap what analysts estimate could be a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions. Hims, ...
AOL

Hims stock price reacts strongly to crucial FDA review

Hims & Hers (HIMS) has caught a powerful new tailwind, and the market is treating peptides as more than a short-lived headline. The immediate catalyst was the FDA’s decision to hold a July 23-24 ...
Hosted on MSN

HIMS stock breaks above $30 ahead of upcoming FDA peptide review: Analysts eye next growth catalyst

・The Pharmacy Compounding Advisory Committee is set to meet next month to determine whether seven peptides are added to the 503A bulk substances list. ・Leerink sees potential approval as an upside ...
The Motley Fool

Stock Market Today, April 16: Hims & Hers Health Jumps on FDA Review of Compounded Peptide Therapies

S&P 500 added 0.23% to finish Thursday’s session at 7,039, while the Nasdaq Composite rose 0.36% to close at 24,103. Across telehealth and online health services, peers were mixed: Teladoc Health ...